Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 21;11(1):180.
doi: 10.1038/s41531-025-01038-4.

Formation of seeding-competent α-synuclein aggregates in parkin-deficient iPSC-derived human neurons

Affiliations

Formation of seeding-competent α-synuclein aggregates in parkin-deficient iPSC-derived human neurons

Sissel Ida Schmidt et al. NPJ Parkinsons Dis. .

Abstract

Loss-of-function mutations in PARK2 (parkin) cause early-onset familial Parkinson's disease (PD) and may also contribute to sporadic PD. While Lewy bodies, enriched in aggregated phosphorylated α-synuclein (α-Syn), are typical in PD, their presence in PARK2-mediated PD remains debated. Using human isogenic PARK2-/- induced pluripotent stem cell-derived neurons, we investigated α-Syn pathology under parkin deficiency. PARK2-/- neurons showed elevated intracellular aggregated and total α-Syn levels, increased α-Syn release, and higher levels of aggregation-inducing α-Syn seeds. These neurons also displayed more pSer129 α-Syn+ inclusions, which were further enhanced by α-Syn preformed fibril (PFF) exposure. Moreover, we identified synaptic loss in the PARK2-/- neurons, exacerbated by PFF treatment, and dysregulated Ca2+ homeostasis consistent with enhanced activity of the smooth endoplasmic reticulum Ca2+-ATPase (SERCA). Our data provide an important contribution to the debate on the role of α-Syn in the pathology of PARK2-related PD and challenge the view of PARK2-related PD as a non-synucleinopathy.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. General characterization of differentiated cultures.
A Graphical overview of the applied dopaminergic (DA) differentiation protocol for differentiation of iPSC-derived PARK2−/− and isogenic control NSCs. B Immunofluorescence staining of day 45 differentiated cultures for tyrosine hydroxylase (TH, dopaminergic neuronal marker), microtubule-associated protein 2 (MAP2, mature neuronal marker), FOXA2 (midbrain dopaminergic neuronal marker), β-tubulin-III (BTUB, general neuronal marker), glial-acidic fibrillary protein (GFAP, astrocyte marker), α-Synuclein (α-Syn), and synaptophysin (SYN, presynaptic marker). The nuclei were stained with DAPI (blue). Scale bar = 50 µm. CE Quantification of MAP2+ mature neurons, TH+ DA neurons, and GFAP+ astrocytes showed no difference in the differentiation capacity of PARK2−/− and isogenic control cells. Mean ± SEM, n = 7-15 coverslips from 3-5 independent differentiations. Statistical analysis: Student’s t-test, NS not significant.
Fig. 2
Fig. 2. Increased α-Syn aggregation in PARK2−/− neurons.
AC ELISA for total α-Syn and aggregated α-Syn (aggregate specific MJF-14-6-4-2 antibody). Mean ± SEM, n = 6 cell lysate samples from 3 independent differentiations. D Release of α-Syn to the culture medium was measured using a sensitive MesoScale immunoassay for α-Syn. Mean ± SEM, n = 5-6 media samples from 3 independent differentiations. E Day 45 differentiated cultures were immunofluorescence-stained for α-Syn phosphorylated at Ser129 (pSer129, green) in combination with MAP2 (purple) to label neuronal cell bodies, and the nuclei were stained with DAPI (blue). Pictures were acquired randomly with a X20 objective on a Zeiss Observer Z1 microscope. Scale bar = 50 µm. F, G Quantification of total pSer129 α-Syn staining per cell and pSer129+ α-Syn inclusions/cell. Mean ± SEM, n = 10-14 coverslips from 3 independent differentiations. H The presence of templating active α-Syn species in the neuronal cell cultures was investigated using the α-Syn seed amplification assay (SAA). α-Syn aggregation was monitored by tracking the increase in thioflavin T (ThT) fluorescence over 44 h. The dotted line indicates the threshold for a positive ThT signal (defined as >5000 RFU). Lysates from PARK2−/− (grey) and control (blue) cells, extracted in RIPA buffer from three independent differentiations, were tested alongside positive controls (α-Syn PFF) and negative controls (α-Syn without RIPA or cell lysate). Each replicate was analysed in quadruplicate, and the graph represents the mean ± SEM. The table presents the incubation time for each sample to reach a fluorescent signal of 5000 RFU (t5000) and the amount of RIPA buffer added to each reaction. The seeding efficiency of cell extracts correlated with the PARK2−/− phenotype but not with the RIPA content of the samples. I The end ThT signal was measured after 44 h. Mean ± SEM, n = 3 cell lysate samples from 3 independent differentiations. Statistical analysis: Student’s t-test, *p < 0.05, **p < 0.01, ***p < 0.001.
Fig. 3
Fig. 3. Exposure to α-Syn preformed fibrils (PFFs).
A Graphical overview of PFF treatment. PARK2−/− and isogenic control iPSC-derived NSCs were differentiated for 38 days before treatment with human recombinant S129A-α-Syn PFF (14 µg/ml). Excess PFFs were washed out after 24 h, and cells were for 45 days before fixation. B Differentiated cultures were immunofluorescence-stained for pSer129 α-Syn (green) in combination with MAP2 (purple) to label neuronal cell bodies, and the nuclei were stained with DAPI (blue). Pictures were acquired randomly with a X60 objective on a Zeiss Observer Z1 microscope. Scale bar = 20 µm. Scalebar on zoomed images = 10 µm. C Quantification of total pSer129 staining per affected cell. D Affected cells were quantified as the percentage of cells with pSer129 α-Syn inclusion+. This analysis was performed on pictures taken with a X20 objective. E Number of pSer129 α-Syn+ inclusions per affected cell. FH Inclusion size distribution according to small (25-100 pixels), medium (101-300 pixels), and large (>300 pixels) inclusions. Mean ± SEM, n = 10 coverslips from 3 independent differentiations. Statistical analysis: Two-way ANOVA, NS = not significant, *p < 0.05, **p < 0.01, ***p < 0.001. I I3 neurons were transfected with lentivirus encoding sgRNA targeting either PARK2, SNCA or a non-targeting guide (control). Following transfection, neurons were treated with PFFs for 14 days, and pSer129 α-Syn levels were quantified. Mean ± SEM, n = 3 independent experiments. Statistical analysis: paired t-test; dotted lines represent the experimental pairs across genotypes.
Fig. 4
Fig. 4. Cell types affected by α-Syn aggregation.
A Immunofluorescence staining for pSer129 α-Syn (green) in combination with TH (dopaminergic neuronal marker, red), GFAP (astrocyte marker, red), or GABA (GABAergic neurons, red). The nuclei were stained with DAPI (blue). Arrows indicate pSer129 α-Syn+ cells. Pictures were acquired randomly with a X20 objective on a Zeiss Observer Z1 microscope. Scale bar = 50 µm. MesoScale multiplex analysis of cytokine release to the conditioned culture medium from control cultures (B) and PARK2−/− cultures (C). Data are expressed as percentage relative to the vehicle group for each cytokine. Total cytokine release was evaluated as the mean difference per cytokine between vehicle and PFF-treated cultures and is presented for control cultures in (D) and PARK2−/− cultures in (E). The baseline difference in cytokine release between untreated control and PARK2−/− cultures is presented in (F). Mean ± SEM, n = 3-4 samples from 2 independent differentiations. Statistical analysis: Student’st-test, NS not significant, *p < 0.05, **p < 0.01, ***p < 0.001.
Fig. 5
Fig. 5. Reduced synaptic density and increased intracellular Ca2+ in PARK2−/− neurons.
A Immunofluorescence staining for pSer129 α-Syn (green), MAP2 (purple; neuronal cell bodies), and DAPI (blue; nuclei). Pictures were acquired randomly with a X60 objective on a Zeiss Observer Z1 microscope. Scale bar = 20 µm. Scalebar on zoomed neurites = 10 µm. B Immunofluorescence staining for synaptophysin (SYN, red), TH (dopaminergic neurons; green), and DAPI (blue; nuclei). Scale bar = 25 µm. C Quantification of the presynaptic numbers per cell in untreated PARK2−/− and control cultures. Mean ± SEM, n = 9 coverslips from three independent differentiations. Statistical analysis: Student’s t-test, ***p < 0.001. D Representative transmission electron microscopy (TEM) images of synapses in control and PARK2−/− neurons. PSD: postsynaptic density, SC: synaptic cleft, SVs: synaptic vesicles. Scale bar = 100 nm. EG Live-cell Ca2+ imaging with Fluo-4-AM in PARK2−/− and isogenic control cultures treated with thapsigargin (2 µM, added at frame 100 (arrow)). E ∆F/F0 traces over time normalized to the mean control peak values, showing individual (thin lines) and average (bold) responses from two independent experiments (3 movies in each; 150–200 cells/movie). F Representative timelapse pictures of Ca2+ signal at selected timepoints. Scale bar = 50 µm. G Quantification of peak ∆F/F0 values. Mean ± SEM, n = 6 movies from two independent differentiations. Statistical analysis: Student’s t-test, *p < 0.05. HJ Depolarization with KCl (25 mM) was performed at frame 100 (arrow). H ∆F/F0 traces over time normalized to the mean control peak values, shown per experiment (thin lines) and across experiments (bold) from two independent differentiations (3 movies recorded in each; 150–200 cells/movie). I Timelapse pictures showing Ca2+ signal over time. Scale bar = 50 µm. J Peak ∆F/F0 values during depolarization. Mean ± SEM, n = 6 movies from two independent differentiations. Statistical analysis: Student’s t-test, NS not significant.

References

    1. Braak, H. et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging24, 197–211 (2003). - PubMed
    1. Borghammer, P. et al. Neuropathological evidence of body-first vs. brain-first Lewy body disease. Neurobiol. Dis.161, 105557 (2021). - PubMed
    1. Poewe, W. et al. Parkinson disease. Nat. Rev. Dis. Prim.3, 17013 (2017). - PubMed
    1. Spillantini, M. G. et al. Alpha-synuclein in Lewy bodies. Nature388, 839–840 (1997). - PubMed
    1. Corti, O. et al. Parkinson’s disease: from causes to mechanisms. C. R. Biol.328, 131–142 (2005). - PubMed

LinkOut - more resources